Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
phase 3
Biotech
UPDATED: Taiho’s discontinues ph. 3 trial after DMD miss
Taiho said both cohorts of the trial have been discontinued and that it is considering all possibilities regarding the future of TAS-205.
Gabrielle Masson
Jul 8, 2025 10:17am
FDA delays force Daré to shelve phase 3 plans: WSJ
Apr 17, 2025 3:03pm
Orca prepares to make market plunge after phase 3 win
Mar 17, 2025 7:00am
Amgen’s late-stage obesity trials expected to read out in ‘27
Mar 5, 2025 1:58pm
Boehringer's schizophrenia drug fails trio of phase 3 trials
Jan 16, 2025 11:58am
Galectin's stock halves after phase 3 MASH trial misses goal
Dec 20, 2024 2:40pm
